Three Biotech Giants…But Only Two are Worth Buying

Bernstein's Ronny Gal and team initiated coverage of Regeneron Pharmaceuticals ( REGN ), Biogen ( BIIB ) and Amgen ( AMGN ) today--but only Biogen and Regeneron received outperform ratings. Making the decisions, however, wasn't so easy. They explain why Regeneron got rated Outperform...